30 years of CIK cell therapy: recapitulating the key breakthroughs and future perspective

Emerging evidence from the numerous clinical trials involving cytokine-induced killer (CIK) cell therapy suggests that its optimization in combination with other contemporary cancer therapies in a complementary manner (rather than as competition) will be a key to combat cancer.

Detalles Bibliográficos
Autores principales: Sharma, Amit, Schmidt-Wolf, Ingo G. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8662881/
https://www.ncbi.nlm.nih.gov/pubmed/34886895
http://dx.doi.org/10.1186/s13046-021-02184-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8662881/
https://www.ncbi.nlm.nih.gov/pubmed/34886895
http://dx.doi.org/10.1186/s13046-021-02184-2

Ejemplares similares